ATE543510T1 - Bowman-birk-hemmer-zusammensetzungen zur behandlung von muskelatrophie und degenerativer muskelerkrankung - Google Patents

Bowman-birk-hemmer-zusammensetzungen zur behandlung von muskelatrophie und degenerativer muskelerkrankung

Info

Publication number
ATE543510T1
ATE543510T1 AT04779693T AT04779693T ATE543510T1 AT E543510 T1 ATE543510 T1 AT E543510T1 AT 04779693 T AT04779693 T AT 04779693T AT 04779693 T AT04779693 T AT 04779693T AT E543510 T1 ATE543510 T1 AT E543510T1
Authority
AT
Austria
Prior art keywords
bowman
treatment
muscle
degenerative
birk inhibitor
Prior art date
Application number
AT04779693T
Other languages
English (en)
Inventor
H Sweeney
Carl Morris
Ann Kennedy
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE543510T1 publication Critical patent/ATE543510T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT04779693T 2003-08-01 2004-07-30 Bowman-birk-hemmer-zusammensetzungen zur behandlung von muskelatrophie und degenerativer muskelerkrankung ATE543510T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49169503P 2003-08-01 2003-08-01
PCT/US2004/024718 WO2005011596A2 (en) 2003-08-01 2004-07-30 Bowman-birk inhibitor compositions for treatment of muscular atrophy and degenerative muscle disease

Publications (1)

Publication Number Publication Date
ATE543510T1 true ATE543510T1 (de) 2012-02-15

Family

ID=34115537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04779693T ATE543510T1 (de) 2003-08-01 2004-07-30 Bowman-birk-hemmer-zusammensetzungen zur behandlung von muskelatrophie und degenerativer muskelerkrankung

Country Status (9)

Country Link
US (2) US8017161B2 (de)
EP (2) EP1663262B1 (de)
JP (1) JP4866728B2 (de)
AT (1) ATE543510T1 (de)
AU (1) AU2004260681B2 (de)
CA (1) CA2534358C (de)
DK (1) DK1663262T3 (de)
ES (1) ES2383097T3 (de)
WO (1) WO2005011596A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520319A (ja) * 2016-05-02 2019-07-18 ニュートゥリー カンパニー リミテッド 小豆を含む筋機能改善又は運動遂行能力向上用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US491695A (en) 1893-02-14 Alternating-current dynamo-electric machine
US2596090A (en) * 1949-10-27 1952-05-13 Eastman Kodak Co Method of treating tocopherols
US2891864A (en) * 1956-06-28 1959-06-23 Eastman Kodak Co Vitamin e fortified animal feeds
CA1219764A (en) * 1985-02-05 1987-03-31 Guan-Huei Ho Non-dairy chocolate drink formulation and process
US5217717A (en) * 1990-09-06 1993-06-08 Central Soya Company, Inc. Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
US5961980A (en) * 1996-01-18 1999-10-05 The Trustees Of The University Of Pennsylvania Bowman-birk inhibitor compositions and methods for the treatment of genitourinary diseases
EP1161266A4 (de) * 1999-03-12 2007-09-19 Univ Georgetown Matriptase, ein serinprotease, und dessen verwendungen

Also Published As

Publication number Publication date
US20110301075A1 (en) 2011-12-08
EP1663262B1 (de) 2012-02-01
DK1663262T3 (da) 2012-05-29
AU2004260681A1 (en) 2005-02-10
US8852650B2 (en) 2014-10-07
CA2534358C (en) 2012-11-06
EP1663262A4 (de) 2008-01-09
US20080300179A1 (en) 2008-12-04
ES2383097T3 (es) 2012-06-18
EP1663262A2 (de) 2006-06-07
JP2007501188A (ja) 2007-01-25
JP4866728B2 (ja) 2012-02-01
EP2322208A3 (de) 2011-08-03
EP2322208A2 (de) 2011-05-18
CA2534358A1 (en) 2005-02-10
US8017161B2 (en) 2011-09-13
WO2005011596A2 (en) 2005-02-10
AU2004260681B2 (en) 2010-07-01
WO2005011596A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE329587T1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DK1392282T3 (da) Dermatologiske og kosmetiske sammensætninger, der omfatter et furfurylderivat
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
CL2004000437A1 (es) Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60223923D1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE406884T1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen